期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

β-内酰胺类抗菌药物的替代给药方案 被引量：4

Alternative dosing regimens of β-lactams antibiotics
下载PDF
导出
摘要 随着群体药代动力学和蒙特卡洛模拟法在抗菌药物领域中的深入研究,进一步验证了通过增加给药频率、延长输注及持续输注的替代给药方案能够明显改善β-内酰胺类抗菌药物的药效学性质,并逐渐取代其传统给药方案。本文就头孢吡肟、美洛培南、哌拉西林/他唑巴坦的替代给药方案的建立做一综述。 Along with the deepening research about population pharmacokinetic and monte carlo simulation in the fields of antibiotics,the alternative dosing regimens applying more frequent dosing,prolonged and continuous infusion is verified to significantly improve the effects of β-lactam antibiotics and gradually replace traditional dosing regimens.This article would take the establishment of the alternative dosing regimens of cefepime,meropenem,piperacillin /tazobactam as examples to make a comprehensive review.
作者 肖宇博 葛卫红
机构地区 南京大学医学院附属鼓楼医院 中国药科大学药学院
出处 《实用药物与临床》 CAS 2013年第9期848-852,共5页 Practical Pharmacy and Clinical Remedies
关键词 Β-内酰胺类 抗生素 替代给药方案 β-lactams Antibiotics Alternative dosing regimen
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献28

  • 1Craig WA.Pharmacokinetic/pharmacodynamic parameters:rationale for antibacterial dosing of mice and men[J].Clin Infect Dis,1998,26(1):1-10,quiz 11-12.
  • 2MacGowan A.Revisiting Beta-lactams-PK/PD improves dosing of old antibiotics[J].Curr Opin Pharmacol,2011,11(5):470-476.
  • 3Roos JF,Bulitta J,Lipman J,et al.Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units[J].J Antimicrob Chemother,2006,58(5):987-993.
  • 4Tam VH,McKinnon PS,Akins RL,et al.Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function[J].Antimicrob Agents Chemother,2003,47(6):1853-1861.
  • 5Kuti JL,Dandekar PK,Nightingale CH,et al.Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem[J].J Clin Pharmacol,2003,43(10):1116-1123.
  • 6Lomaestro BM,Drusano GL.Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation[J].Antimicrob Agents Chemother,2005,49(1):461-463.
  • 7Cheatham SC,Kays MB,Smith DW,et al.Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients[J].Pharmacotherapy,2008,28(6):691-698.
  • 8Zelenitsky SA,Ariano RE,Zhanel GG.Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit(ICU)population based on Canadian surveillance data[J].J Antimicrob Chemother,2011,66(2):343-349.
  • 9Koomanachai P,Bulik CC,Kuti JL,et al.Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States[J].Clin Ther,2010,32(4):766-779.
  • 10Shea KM,Cheatham SC,Smith DW,et al.Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients[J].Ann Pharmacother,2009,43(11):1747-1754.

同被引文献60

  • 1王玉和,黎俊华.帕珠沙星注射液与左氧氟沙星注射液治疗急性细菌性感染的药物经济学评价[J].中国药学杂志,2007,42(4):318-320. 被引量：3
  • 2卫生部抗生素临床药理基地.抗菌药物临床研究指导原则.中国临床药理学杂志,1987,2:189-191.
  • 3Edwards JR. Meropenem: a microbiological overview[.I]. JAntimicrob Chemother, 1995,36(Suppl A) : 1.
  • 4Jadad AR, Moore RA, Carroll D, et al. Assessing the qu- ality of reports of randomized clinical trials: is blinding necessary?[J]. Control Clin Trials, 1996,17( 1 ) : 1.
  • 5Wells GA, Shea B, O' Connell D, et al. The Newcastle- Ottawa Scale (NOS) for assessing the quality if nonran- domized studies in meta-analyses[EB/OL]. ( 2014 ) [2014- 09-1].http://www.ohri.ca/programs/clinical_epidemiology/ oxford.htm.
  • 6Chytra I, Stepan M, Benes J, et al. Clinical and microbi- ological efficacy of continuous versus intermittent applica- tion of meropenem in critically ill patients: a randomized open-label controlled trial[J]. Crit Care, 2012, 16 (3) : Rl13.
  • 7Feher C, Rovira M, Soriano A, et al. Effect of meropen- em administration in extended infusion on the clinical out- come of febrile neutropenia: a retrospective observational study[J]. JAntimicrob Chemother, 2014,69 (9) : 2 556.
  • 8Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-asso-ciated pneumonia due to gram-negative bacilli[J]. Ann Pharmaeother, 2006,40 ( 2 ) : 219.
  • 9Itabashi S. Clinical efficacy of prolonged (4 hour) drip in- fusion of meropenem against severe pneumonia[J]. Jpn J Antibiot,2007,60(3) : 161.
  • 10Okimoto N, Ishiga M, Nanba F, et al. Clinical effects of continuous infusion and intermittent infusion of meropen-em on bacterial pneumonia in the elderly[J]. Nihon Kokyu- ki Gakkai Zasshi, 2009,47( 7 ) : 553.

引证文献4

二级引证文献25

实用药物与临床
2013年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部